Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00866697




Registration number
NCT00866697
Ethics application status
Date submitted
19/03/2009
Date registered
20/03/2009
Date last updated
16/02/2021

Titles & IDs
Public title
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Scientific title
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Secondary ID [1] 0 0
2008-004672-50
Secondary ID [2] 0 0
110655
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pazopanib
Treatment: Drugs - Placebo

Placebo comparator: Placebo - matched placebo tablet administered orally once daily for up to 24 months

Experimental: Pazopanib - Pazopanib tablet administered orally at 800 mg once daily for up to 24 months


Treatment: Drugs: Pazopanib
Pazopanib 800 mg tablet daily for 104 weeks (24 months)

Treatment: Drugs: Placebo
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Investigator-assessed Progression-free Survival (PFS)
Timepoint [1] 0 0
From the date of randomization until the date of progression or death due to any cause (median time of follow-up was 17.9 months for pazopanib and 12.3 months for placebo)
Secondary outcome [1] 0 0
Overall Survival - Median
Timepoint [1] 0 0
From the date of randomization until the date of death due to any cause up to approximately 25 months
Secondary outcome [2] 0 0
Overall Survival: Number of Participants Experiencing Death
Timepoint [2] 0 0
From the date of randomization until the date of death due to any cause up to approximately 25 months
Secondary outcome [3] 0 0
Progression-free Survival Per Gynecologic Cancer Intergroup (GCIG) Criteria
Timepoint [3] 0 0
From the date of randomization until the date of progression per GCIG criteria or death due to any cause (median time of follow-up was 16.8 months for pazopanib and 11.9 months for placebo)
Secondary outcome [4] 0 0
3-year Progression-free Survival
Timepoint [4] 0 0
Up to 3 years after randomization
Secondary outcome [5] 0 0
Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [5] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [6] 0 0
Change From Baseline in QLQ-OV-28 Module Attitude to Disease/Treatment Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [6] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [7] 0 0
Change From Baseline in QLQ-OV-28 Module Body Image Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [7] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [8] 0 0
Change From Baseline in QLQ-OV-28 Module Peripheral Neuropathy (PN) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [8] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [9] 0 0
Change From Baseline in QLQ-OV-28 Module Abdominal (AB)/Gastrointestinal (GI) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [9] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [10] 0 0
Change From Baseline in QLQ-OV-28 Module Hormonal/Menopausal Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [10] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [11] 0 0
Change From Baseline in QLQ-OV-28 Module Sexuality Functional on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [11] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [12] 0 0
Change From Baseline in QLQ-OV-28 Module Other Chemotherapy Side Effects (SE) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [12] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [13] 0 0
Change From Baseline in the EuroQOL EQ-5D (Five Dimensions) Thermometer Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [13] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [14] 0 0
Change From Baseline in the EQ-5D (Five Dimensions) Utility Score at Week 13 and Months 7, 10, 13, 16, and 25
Timepoint [14] 0 0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Secondary outcome [15] 0 0
Number of Participants With the Indicated Grade 2, 3, and 4 On-therapy Adverse Events Occurring in >=10% of Participants in Either Treatment Arm
Timepoint [15] 0 0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Secondary outcome [16] 0 0
Number of Participants With the Indicated On-therapy Hematology Grade Shifts From Baseline Grade
Timepoint [16] 0 0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Secondary outcome [17] 0 0
Number of Participants With the Indicated On-therapy Chemistry Grade Shifts From Baseline Grade
Timepoint [17] 0 0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Secondary outcome [18] 0 0
Number of Participants With the Indicated Treatment-emergent Thyroid-stimulating Hormone (TSH) Elevations Above 5 Million Units Per Liter (MU/L)
Timepoint [18] 0 0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)

Eligibility
Key inclusion criteria
* written informed consent
* At least 18 years old.
* Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
* Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
* No evidence of disease progression
* ECOG status of 0 or 2
* Able to swallow and retain oral medication.
* Adequate hematologic, hepatic, and renal system function as follows:

Hematologic

* Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
* Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
* Platelets at least 100 X 10^9/L
* Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
* Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
* Total bilirubin up to 1.5 X ULN
* AST and ALT up to 2.5 X ULN Renal
* Serum creatinine up to 1.5 mg/dL

Or, if greater than 1.5 mg/dL:

Calculated creatinine clearance at least 50 mL/min Urine Protein

* Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24- hour urine protein analysis.
* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
* Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
* Clinically significant gastrointestinal abnormalities
* Prolongation of corrected QT interval (QTc) > 480 msecs
* History of any one or more cardiovascular conditions within the past 6 months prior to randomization
* Cardiac angioplasty or stenting
* Myocardial infarction
* Unstable angina
* Symptomatic peripheral vascular disease

* Class III or IV congestive heart failure
* Poorly controlled hypertension
* History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
* Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
* Evidence of active bleeding or bleeding diathesis.
* Hemoptysis within 6 weeks prior to randomization.
* Endobronchial metastases.
* Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
* Investigational or anti-VEGF anticancer therapy prior to study randomization.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
* Invasive malignancies that showed activity of disease within 5 years prior to randomization

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/05/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/08/2017
Sample size
Target
Accrual to date
Final
940
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Camperdown
Recruitment hospital [2] 0 0
Novartis Investigative Site - Liverpool
Recruitment hospital [3] 0 0
Novartis Investigative Site - Randwick
Recruitment hospital [4] 0 0
Novartis Investigative Site - Waratah
Recruitment hospital [5] 0 0
Novartis Investigative Site - Herston
Recruitment hospital [6] 0 0
Novartis Investigative Site - South Brisbane
Recruitment hospital [7] 0 0
Novartis Investigative Site - Adelaide
Recruitment hospital [8] 0 0
Novartis Investigative Site - Hobart
Recruitment hospital [9] 0 0
Novartis Investigative Site - Malvern
Recruitment hospital [10] 0 0
Novartis Investigative Site - Parkville
Recruitment hospital [11] 0 0
Novartis Investigative Site - Wodonga
Recruitment hospital [12] 0 0
Novartis Investigative Site - Nedlands
Recruitment hospital [13] 0 0
Novartis Investigative Site - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2031 - Randwick
Recruitment postcode(s) [4] 0 0
2298 - Waratah
Recruitment postcode(s) [5] 0 0
4029 - Herston
Recruitment postcode(s) [6] 0 0
4101 - South Brisbane
Recruitment postcode(s) [7] 0 0
5000 - Adelaide
Recruitment postcode(s) [8] 0 0
7000 - Hobart
Recruitment postcode(s) [9] 0 0
3144 - Malvern
Recruitment postcode(s) [10] 0 0
3052 - Parkville
Recruitment postcode(s) [11] 0 0
3690 - Wodonga
Recruitment postcode(s) [12] 0 0
6009 - Nedlands
Recruitment postcode(s) [13] 0 0
3084 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
New Jersey
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
United States of America
State/province [6] 0 0
Virginia
Country [7] 0 0
Austria
State/province [7] 0 0
Graz
Country [8] 0 0
Austria
State/province [8] 0 0
Innsbruck
Country [9] 0 0
Austria
State/province [9] 0 0
Klagenfurt Am Woerthersee
Country [10] 0 0
Austria
State/province [10] 0 0
Korneuburg
Country [11] 0 0
Austria
State/province [11] 0 0
Krems
Country [12] 0 0
Austria
State/province [12] 0 0
Leoben
Country [13] 0 0
Austria
State/province [13] 0 0
Linz
Country [14] 0 0
Austria
State/province [14] 0 0
Oberpullendorf
Country [15] 0 0
Austria
State/province [15] 0 0
Wien
Country [16] 0 0
Belgium
State/province [16] 0 0
Bonheiden
Country [17] 0 0
Belgium
State/province [17] 0 0
Duffel
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Kortrijk
Country [20] 0 0
Belgium
State/province [20] 0 0
Leuven
Country [21] 0 0
Belgium
State/province [21] 0 0
Libramont
Country [22] 0 0
Belgium
State/province [22] 0 0
Liege
Country [23] 0 0
Belgium
State/province [23] 0 0
Namur
Country [24] 0 0
Belgium
State/province [24] 0 0
Oostende
Country [25] 0 0
China
State/province [25] 0 0
Guangdong
Country [26] 0 0
China
State/province [26] 0 0
Jiangsu
Country [27] 0 0
China
State/province [27] 0 0
Liaoning
Country [28] 0 0
China
State/province [28] 0 0
Shandong
Country [29] 0 0
China
State/province [29] 0 0
Zhejiang
Country [30] 0 0
China
State/province [30] 0 0
Beijing
Country [31] 0 0
China
State/province [31] 0 0
Shanghai
Country [32] 0 0
China
State/province [32] 0 0
Tianjin
Country [33] 0 0
Denmark
State/province [33] 0 0
Aalborg
Country [34] 0 0
Denmark
State/province [34] 0 0
Herlev
Country [35] 0 0
Denmark
State/province [35] 0 0
Herning
Country [36] 0 0
Denmark
State/province [36] 0 0
Koebenhavn Oe
Country [37] 0 0
France
State/province [37] 0 0
ANGERS Cedex 2
Country [38] 0 0
France
State/province [38] 0 0
Avignon cedex
Country [39] 0 0
France
State/province [39] 0 0
Besancon Cedex
Country [40] 0 0
France
State/province [40] 0 0
Bordeaux
Country [41] 0 0
France
State/province [41] 0 0
Bourg en Bresse Cedex
Country [42] 0 0
France
State/province [42] 0 0
Brest Cedex
Country [43] 0 0
France
State/province [43] 0 0
Brive La Gaillarde
Country [44] 0 0
France
State/province [44] 0 0
Caen Cedex 05
Country [45] 0 0
France
State/province [45] 0 0
Clermont-Ferrand cedex
Country [46] 0 0
France
State/province [46] 0 0
Colmar Cedex
Country [47] 0 0
France
State/province [47] 0 0
Dax Cedex
Country [48] 0 0
France
State/province [48] 0 0
Grenoble Cedex 09
Country [49] 0 0
France
State/province [49] 0 0
Grenoble Cedex
Country [50] 0 0
France
State/province [50] 0 0
La Roche sur Yon Cedex 9
Country [51] 0 0
France
State/province [51] 0 0
Le Chesnay Cedex
Country [52] 0 0
France
State/province [52] 0 0
Le Mans
Country [53] 0 0
France
State/province [53] 0 0
Lille Cedex
Country [54] 0 0
France
State/province [54] 0 0
Lille
Country [55] 0 0
France
State/province [55] 0 0
Lorient cedex
Country [56] 0 0
France
State/province [56] 0 0
Lyon Cedex 08
Country [57] 0 0
France
State/province [57] 0 0
Marseille cedex
Country [58] 0 0
France
State/province [58] 0 0
Metz Cedex 03
Country [59] 0 0
France
State/province [59] 0 0
Mont de Marsan
Country [60] 0 0
France
State/province [60] 0 0
Montpellier cedex 5
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Mougins Cedex 2
Country [63] 0 0
France
State/province [63] 0 0
Nancy
Country [64] 0 0
France
State/province [64] 0 0
Nantes Cedex 2
Country [65] 0 0
France
State/province [65] 0 0
Nice Cedex 2
Country [66] 0 0
France
State/province [66] 0 0
Nimes
Country [67] 0 0
France
State/province [67] 0 0
Orleans
Country [68] 0 0
France
State/province [68] 0 0
Paris cedex 05
Country [69] 0 0
France
State/province [69] 0 0
Paris Cedex 10
Country [70] 0 0
France
State/province [70] 0 0
Paris Cedex 20
Country [71] 0 0
France
State/province [71] 0 0
Paris Cedex 4
Country [72] 0 0
France
State/province [72] 0 0
Paris
Country [73] 0 0
France
State/province [73] 0 0
Perigueux Cedex
Country [74] 0 0
France
State/province [74] 0 0
Perin Sur Mer
Country [75] 0 0
France
State/province [75] 0 0
Pierre-Benite Cedex
Country [76] 0 0
France
State/province [76] 0 0
Reims Cedex
Country [77] 0 0
France
State/province [77] 0 0
Rouen
Country [78] 0 0
France
State/province [78] 0 0
Saint-Herblain
Country [79] 0 0
France
State/province [79] 0 0
Saint-Priest en Jarez
Country [80] 0 0
France
State/province [80] 0 0
Strasbourg Cedex
Country [81] 0 0
France
State/province [81] 0 0
Strasbourg
Country [82] 0 0
France
State/province [82] 0 0
Suresnes
Country [83] 0 0
France
State/province [83] 0 0
Thonon-les-Bains
Country [84] 0 0
France
State/province [84] 0 0
Vandoeuvre-Les-Nancy
Country [85] 0 0
Germany
State/province [85] 0 0
Baden-Wuerttemberg
Country [86] 0 0
Germany
State/province [86] 0 0
Bayern
Country [87] 0 0
Germany
State/province [87] 0 0
Hessen
Country [88] 0 0
Germany
State/province [88] 0 0
Mecklenburg-Vorpommern
Country [89] 0 0
Germany
State/province [89] 0 0
Niedersachsen
Country [90] 0 0
Germany
State/province [90] 0 0
Nordrhein-Westfalen
Country [91] 0 0
Germany
State/province [91] 0 0
Rheinland-Pfalz
Country [92] 0 0
Germany
State/province [92] 0 0
Sachsen-Anhalt
Country [93] 0 0
Germany
State/province [93] 0 0
Sachsen
Country [94] 0 0
Germany
State/province [94] 0 0
Schleswig-Holstein
Country [95] 0 0
Germany
State/province [95] 0 0
Thueringen
Country [96] 0 0
Germany
State/province [96] 0 0
Berlin
Country [97] 0 0
Germany
State/province [97] 0 0
Hamburg
Country [98] 0 0
Hong Kong
State/province [98] 0 0
Hong Kong
Country [99] 0 0
Hong Kong
State/province [99] 0 0
Kowloon
Country [100] 0 0
Ireland
State/province [100] 0 0
Dublin
Country [101] 0 0
Ireland
State/province [101] 0 0
Waterford
Country [102] 0 0
Ireland
State/province [102] 0 0
Wilton, Cork
Country [103] 0 0
Italy
State/province [103] 0 0
Basilicata
Country [104] 0 0
Italy
State/province [104] 0 0
Campania
Country [105] 0 0
Italy
State/province [105] 0 0
Emilia-Romagna
Country [106] 0 0
Italy
State/province [106] 0 0
Friuli-Venezia-Giulia
Country [107] 0 0
Italy
State/province [107] 0 0
Lazio
Country [108] 0 0
Italy
State/province [108] 0 0
Lombardia
Country [109] 0 0
Italy
State/province [109] 0 0
Molise
Country [110] 0 0
Italy
State/province [110] 0 0
Piemonte
Country [111] 0 0
Italy
State/province [111] 0 0
Puglia
Country [112] 0 0
Italy
State/province [112] 0 0
Sicilia
Country [113] 0 0
Italy
State/province [113] 0 0
Umbria
Country [114] 0 0
Italy
State/province [114] 0 0
Veneto
Country [115] 0 0
Japan
State/province [115] 0 0
Ehime
Country [116] 0 0
Japan
State/province [116] 0 0
Fukuoka
Country [117] 0 0
Japan
State/province [117] 0 0
Hiroshima
Country [118] 0 0
Japan
State/province [118] 0 0
Hokkaido
Country [119] 0 0
Japan
State/province [119] 0 0
Iwate
Country [120] 0 0
Japan
State/province [120] 0 0
Kagoshima
Country [121] 0 0
Japan
State/province [121] 0 0
Miyagi
Country [122] 0 0
Japan
State/province [122] 0 0
Osaka
Country [123] 0 0
Japan
State/province [123] 0 0
Saitama
Country [124] 0 0
Japan
State/province [124] 0 0
Tokyo
Country [125] 0 0
Japan
State/province [125] 0 0
Tottori
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Goyang-si, Gyeonggi-do
Country [127] 0 0
Korea, Republic of
State/province [127] 0 0
Kangnam-Ku ,Seoul
Country [128] 0 0
Korea, Republic of
State/province [128] 0 0
Seoul
Country [129] 0 0
Norway
State/province [129] 0 0
Bergen
Country [130] 0 0
Norway
State/province [130] 0 0
Oslo
Country [131] 0 0
Norway
State/province [131] 0 0
Stavanger
Country [132] 0 0
Norway
State/province [132] 0 0
Tromso
Country [133] 0 0
Spain
State/province [133] 0 0
Alcorcon (Madrid)
Country [134] 0 0
Spain
State/province [134] 0 0
Barcelona
Country [135] 0 0
Spain
State/province [135] 0 0
Cartagena (Murcia)
Country [136] 0 0
Spain
State/province [136] 0 0
Elche
Country [137] 0 0
Spain
State/province [137] 0 0
Lerida
Country [138] 0 0
Spain
State/province [138] 0 0
Madrid
Country [139] 0 0
Spain
State/province [139] 0 0
Murcia (El Palmar)
Country [140] 0 0
Spain
State/province [140] 0 0
Palma de Mallorca
Country [141] 0 0
Spain
State/province [141] 0 0
Pamplona
Country [142] 0 0
Spain
State/province [142] 0 0
Sabadell (Barcelona)
Country [143] 0 0
Spain
State/province [143] 0 0
San Sebastian
Country [144] 0 0
Spain
State/province [144] 0 0
Santiago de Compostela
Country [145] 0 0
Spain
State/province [145] 0 0
Terrassa
Country [146] 0 0
Spain
State/province [146] 0 0
Valencia
Country [147] 0 0
Spain
State/province [147] 0 0
Zaragoza
Country [148] 0 0
Sweden
State/province [148] 0 0
Linkoping
Country [149] 0 0
Sweden
State/province [149] 0 0
Lund
Country [150] 0 0
Sweden
State/province [150] 0 0
Stockholm
Country [151] 0 0
Sweden
State/province [151] 0 0
Uppsala
Country [152] 0 0
Taiwan
State/province [152] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
GlaxoSmithKline
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
Trial website
https://clinicaltrials.gov/study/NCT00866697
Trial related presentations / publications
Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. doi: 10.1016/j.ygyno.2019.08.024. Epub 2019 Sep 10.
Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.
Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. doi: 10.1186/s12910-016-0144-y.
Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. doi: 10.1097/IGC.0000000000000602.
Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00866697